PIONYR IMMUNOTHERAPEUTICS
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
PIONYR IMMUNOTHERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.pionyrtx.com
Total Employee:
51+
Status:
Active
Contact:
(415)226-7503
Email Addresses:
[email protected]
Total Funding:
352 M USD
Technology used in webpage:
SPF Amazon AWS Global Accelerator Namefind
Similar Organizations
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Impulse Dynamics
Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF).
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
RefleXion Medical
RefleXion Medical is a developer of biologically-guided radiotherapy systems for patients with cancer.
Reneo Pharmaceuticals
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Vedanta Biosciences
Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gilead Sciences
Gilead Sciences investment in Corporate Round - Pionyr Immunotherapeutics
JLABS
JLABS investment in Series B - Pionyr Immunotherapeutics
SV Health Investors
SV Health Investors investment in Series B - Pionyr Immunotherapeutics
Stephen Hoffman
Stephen Hoffman investment in Series B - Pionyr Immunotherapeutics
Vida Ventures
Vida Ventures investment in Series B - Pionyr Immunotherapeutics
OrbiMed
OrbiMed investment in Series B - Pionyr Immunotherapeutics
Mission Bay Capital
Mission Bay Capital investment in Series B - Pionyr Immunotherapeutics
QB3
QB3 investment in Series B - Pionyr Immunotherapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Pionyr Immunotherapeutics
Sofinnova Investments
Sofinnova Investments investment in Series B - Pionyr Immunotherapeutics
Official Site Inspections
http://www.pionyrtx.com
- Host name: ewhserver1302.edgewebhosting.net
- IP address: 69.63.140.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pionyr Immunotherapeutics"
Pionyr Immunotherapeutics - Crunchbase Company …
Organization. Pionyr Immunotherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Pionyr Immunotherapeutics is a developer of cancer immunotherapies …See details»
Pionyr Immunotherapeutics - Overview, News & Similar
Mar 1, 2023 View Pionyr Immunotherapeutics (www.pionyrtx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Pionyr Immunotherapeutics - LinkedIn
Pionyr Immunotherapeutics | 4,867 followers on LinkedIn. The New Frontier of Immuno-Oncology | In 2015, Pionyr Immunotherapeutics embarked on a journey to forge a new path in immuno-oncology for ...See details»
Gilead Sciences Secures Exclusive Option to Acquire Pionyr ...
Jun 23, 2020 For more information, please visit www.pionyrtx.com. About Gilead Sciences. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, …See details»
Pionyr Immunotherapeutics Company Overview, Contact Details ...
Jun 23, 2020 Acquisition Opportunity Pionyr Immunotherapeutics was recently acquired by Ikena Oncology Inc, presenting a potential sales opportunity for service providers catering to newly …See details»
Pionyr - VentureRadar
"Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors and …See details»
Pionyr and Abcam extend partnership to evaluate
Jun 22, 2021 [email protected]. About Abcam. As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to …See details»
Pionyr Immunotherapeutics Presents on Third Myeloid-Directed ...
Mar 22, 2022 For more information, please visit www.pionyrtx.com. Follow @Pionyrimmunotherapeutics on LinkedIn. Follow @Pionyrimmunotx on Twitter. SOURCE …See details»
PIONYR Immunotherapeutics Announces Key Leadership Team …
Aug 27, 2019 PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages - Alicia Levey, Ph.D., joins as …See details»
Pionyr Immunotherapeutics Adds Three Leading Oncology …
May 3, 2022 Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s antitumor immunitySee details»
Pionyr Immunotherapeutics Doses First Patient in Phase 1b …
Mar 8, 2022 SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning TM antibody …See details»
Gilead Sciences Secures Exclusive Option to Acquire Pionyr ...
Jun 23, 2020 Contacts. Gilead Contacts: Douglas Maffei, PhD, Investors (650) 522-2739 Marni Kottle, Media (650) 522-5388 Pionyr Contact: Jason Spark CanaleComm, for Pionyr (619) 849 …See details»
Pionyr Immunotherapeutics Doses First Patient in Phase 1b
Mar 8, 2022 Pionyr’s additional investors include New Enterprise Associates, OrbiMed, SV Health Investors, Sofinnova Ventures, Vida Ventures, Osage University Partners, Mission Bay …See details»
Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting …
May 25, 2023 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuningâ„¢ antibody …See details»
PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of …
Nov 18, 2020 SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that …See details»
PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study
Nov 18, 2020 SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that …See details»
Pionyr and Abcam extend partnership to evaluate TREM2 …
Jun 22, 2021 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class …See details»
Pionyr Immunotherapeutics to Present on Myeloid Tuning …
Jun 16, 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuningâ„¢ antibody …See details»
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2
May 26, 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning TM antibody …See details»
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2 ... - BioSpace
May 26, 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning TM antibody …See details»